What study endpoints can and cannot do
Wound closure, tissue repair, and safety observations inside specific studies can answer those study questions. They do not establish universal pre-use, on-use, or follow-up laboratory testing.
What this evidence review covers
Explain that neither parent-peptide trials nor preclinical repair studies establish a TB-500 monitoring panel.
- Fragment evidence gap
- Measurements in full-length trials are not a fragment protocol
- Outcome biomarkers versus safety monitoring
- No five-lab checklist
Source-backed findings
Each claim below is tied to the evidence class that can support it. Commercial listing data and clinical evidence remain separate.
regulatory
FDA reports no identified human exposure data for the fragment.
entity mismatch
Full-length Tβ4 studies cannot supply a validated fragment monitoring plan.
| Evidence class | What the source supports |
|---|---|
| regulatory | FDA reports no identified human exposure data for the fragment. |
| entity mismatch | Full-length Tβ4 studies cannot supply a validated fragment monitoring plan. |
Source-by-source evidence notes
These notes state what each inspected source can support and the boundary that should not be crossed when interpreting it.
FDA bulk substances that may present significant safety risks
Evidence class: primary regulatory. What it supports: FDA's BPC-157, injectable GHK-Cu, and TB-500 fragment safety/characterization statements; no identified human TB-500 fragment exposure data.
What it does not establish: A diagnosis, individual risk estimate, or claim that topical GHK-Cu and injectable GHK-Cu share one risk profile.
Intravenous full-length thymosin beta-4 in healthy volunteers
Evidence class: primary randomized phase 1 entity mismatch. What it supports: Short-term tolerability and pharmacokinetics of characterized full-length thymosin beta-4 in healthy volunteers.
What it does not establish: TB-500 fragment identity, TB-500 safety, injury healing, retail-product quality, or a TB-500 dose.
Full-length thymosin beta-4 ophthalmic solution phase 2 trial
Evidence class: primary randomized phase 2 entity and route mismatch. What it supports: 72-person ophthalmic full-length Tβ4 study; primary endpoints were not significant; selected secondary endpoints differed.
What it does not establish: TB-500 fragment efficacy, systemic administration, injury protocols, or retail-vial safety.
Questions this page answers
Which labs should be checked?
No fragment-specific panel is supported; do not infer one from parent-peptide research.
Do wound-healing biomarkers prove response?
No validated clinical response biomarker for TB-500 fragment was identified.
What remains unresolved
- No human fragment monitoring evidence.
- No target ranges or schedule.
- No efficacy biomarker validation.